iBio Announces Unaudited Preliminary Financial Results
iBio, Inc. (NYSEA:IBIO), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides […]